3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Small Cell Lung Carcinoma
2
Neuroendocrine Tumors
1
Neuroendocrine Prostate Cancer
1
Neoplasms
1
Lung Neoplasms
1
Interventions
Everolimus
16
Octreotide
6
pembrolizumab
5
lanreotide
5
Sunitinib
5
Magnetic Resonance Spectroscopy
5
gallium Ga 68 dotatate
4
cabozantinib
4
Nivolumab
4
Carboplatin
4
telotristat ethyl
3
lenvatinib
3
arginyllysine
3
Specimen Handling
3
Etoposide
3
Erlotinib Hydrochloride
3
Bevacizumab
3
surufatinib
2
pazopanib
2
pasireotide
2
lutetium Lu 177 dotatate
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Temozolomide
2
Sorafenib
2
Phantoms, Imaging
2
Paclitaxel
2
Oxaliplatin
2
Ipilimumab
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neuroendocrine Tumors
×
AMG 757
×
Clear all
NCT06502977
2026-04-15
DeLLphi-307
Amgen
Phase 2
Active not recruiting
32 enrolled
9 charts